EA201692497A1 - Биомаркеры ответа на ингибиторы ezh2 - Google Patents

Биомаркеры ответа на ингибиторы ezh2

Info

Publication number
EA201692497A1
EA201692497A1 EA201692497A EA201692497A EA201692497A1 EA 201692497 A1 EA201692497 A1 EA 201692497A1 EA 201692497 A EA201692497 A EA 201692497A EA 201692497 A EA201692497 A EA 201692497A EA 201692497 A1 EA201692497 A1 EA 201692497A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biomarkers
level
ezh2
response
bar1
Prior art date
Application number
EA201692497A
Other languages
English (en)
Other versions
EA036889B1 (ru
Inventor
Росс Левайн
Линдсей Лейфэйв
Омар Абдель-Вахаб
Original Assignee
Мемориал Слоан-Кеттеринг Кэнсер Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоан-Кеттеринг Кэнсер Сентер filed Critical Мемориал Слоан-Кеттеринг Кэнсер Сентер
Publication of EA201692497A1 publication Critical patent/EA201692497A1/ru
Publication of EA036889B1 publication Critical patent/EA036889B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Описываемый в настоящем документе объект изобретения относится к применению одного или более биомаркеров для оценки вероятности того, что ингибитор EZH2 проявит противоопухолевое действие у индивидуума. Он основан, по меньшей мере частично, на открытии, что потеря ВАР1 приводит к возрастанию уровня экспрессии и активности EZH2. В конкретном неограничивающем варианте осуществления способ включает получение у индивидуума образца злокачественной опухоли и определение в образце уровня экспрессии биомаркера ВАР1, где, если биомаркер ВАР1 отсутствует или экспрессируется в злокачественной опухоли на более низком уровне по сравнению с эталонным контрольным уровнем, тогда проводят введение терапевтически эффективного количества ингибитора EZH2 для получения противоопухолевого действия.
EA201692497A 2014-06-19 2015-06-19 Биомаркеры ответа на ингибиторы ezh2 EA036889B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19
PCT/US2015/036677 WO2015196064A1 (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Publications (2)

Publication Number Publication Date
EA201692497A1 true EA201692497A1 (ru) 2017-06-30
EA036889B1 EA036889B1 (ru) 2021-01-12

Family

ID=54936135

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692497A EA036889B1 (ru) 2014-06-19 2015-06-19 Биомаркеры ответа на ингибиторы ezh2

Country Status (15)

Country Link
US (1) US20170138946A1 (ru)
EP (1) EP3158086B1 (ru)
JP (1) JP6684230B2 (ru)
KR (1) KR20170020463A (ru)
CN (1) CN106795561B (ru)
AU (1) AU2015276899B2 (ru)
BR (1) BR112016029911A2 (ru)
CA (1) CA2952285A1 (ru)
EA (1) EA036889B1 (ru)
ES (1) ES2870096T3 (ru)
IL (1) IL249443B (ru)
MX (1) MX2016017097A (ru)
SG (2) SG11201610610YA (ru)
WO (1) WO2015196064A1 (ru)
ZA (1) ZA201608555B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
CN109073659B (zh) * 2016-02-16 2022-05-17 新加坡科技研究局 表观基因组分析揭示了原发性胃腺癌的体细胞启动子局面
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
DE69132843T2 (de) 1990-12-06 2002-09-12 Affymetrix Inc N D Ges D Staat Identifizierung von Nukleinsäuren in Proben
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US20030077616A1 (en) 2001-04-19 2003-04-24 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
IL160324A0 (en) 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
AU2003213054A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US20030199001A1 (en) 2002-04-23 2003-10-23 Pitt Aldo M. Sample preparation of biological fluids for proteomic applications
US20080038725A1 (en) 2005-06-20 2008-02-14 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20140011696A1 (en) * 2011-02-16 2014-01-09 Thomas Wiesner Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
KR102587175B1 (ko) 2012-03-12 2023-10-06 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
PL2908823T3 (pl) 2012-10-15 2020-03-31 Epizyme, Inc. Sposoby leczenia nowotworu

Also Published As

Publication number Publication date
EA036889B1 (ru) 2021-01-12
JP2017525337A (ja) 2017-09-07
EP3158086A4 (en) 2018-01-10
CA2952285A1 (en) 2015-12-23
AU2015276899B2 (en) 2021-08-12
EP3158086B1 (en) 2021-03-24
EP3158086A1 (en) 2017-04-26
KR20170020463A (ko) 2017-02-22
IL249443B (en) 2022-05-01
ZA201608555B (en) 2022-05-25
JP6684230B2 (ja) 2020-04-22
MX2016017097A (es) 2017-05-01
US20170138946A1 (en) 2017-05-18
CN106795561B (zh) 2021-04-16
WO2015196064A1 (en) 2015-12-23
AU2015276899A1 (en) 2017-01-05
SG10202007972SA (en) 2020-10-29
SG11201610610YA (en) 2017-01-27
CN106795561A (zh) 2017-05-31
BR112016029911A2 (pt) 2017-10-24
ES2870096T3 (es) 2021-10-26
IL249443A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
EP3134546A4 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EP3140426A4 (en) Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EP3190416A4 (en) Biomarker for predicting sensitivity to protein kinase inhibitor and use thereof
IL278967A (en) Biomarkers to determine the efficacy of immune checkpoint inhibitors
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201692350A1 (ru) Биомаркеры легочной гипертензии
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
DK3283642T3 (da) Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
MX2017003832A (es) Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr.